




Revista Colombiana de REUMATOLOGÍA

www.elsevier.es/rcreuma



Case Report

Rapid responses to golimumab in refractory adult-onset Still's disease: A case report and review of the literature



María Lorena Brance^{a,b}

^a Reumatología y Enfermedades Óseas, Rosario, Argentina

^b Laboratorio de Biología Ósea, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Argentina

ARTICLE INFO

Article history:

Received 3 September 2018

Accepted 22 October 2018

Available online 20 December 2018

Keywords:

Adult-onset Still's disease

Refractory

Golimumab

ABSTRACT

Introduction: Adult onset Still's disease (AOSD) is a systemic inflammatory disorder of unknown etiology. AOSD is generally a mild and self-limiting disease, but it could progress to become chronic. The anemia of chronic diseases may occur in patients with acute or chronic immune activation, and is associated with the production of pro-inflammatory cytokines.

Case report: A 61-year-old woman with several pharyngitis episodes, spiking fever, evanescent salmon-pink skin rash, normocytic normochromic anemia, leucocytosis, thrombocytopenia, polyarthritis, liver dysfunction, marked elevated erythrocyte sedimentation rate and C-reactive protein and, notably high ferritin levels. AOSD was diagnosed after secondary diseases were ruled out. Despite eight months on treatment with high-dose corticosteroids and methotrexate the clinical course the patient worsened, with significant synovitis, joint deformities leading to a worse quality of life and requiring help with activities of daily living. A rapid response to the anti-TNF α golimumab (50 mg/month) was observed from the third month of treatment.

Conclusion: Golimumab improved anemia, serum C-reactive protein levels, polyarthritis and quality of life in a refractory AOSD.

© 2018 Published by Elsevier España, S.L.U. on behalf of Asociación Colombiana de Reumatología.

Rápida respuesta a golimumab en enfermedad de Still del adulto refractaria: presentación de un caso y revisión de la literatura

RESUMEN

Introducción: La enfermedad de Still del adulto (AOSD, por sus siglas en inglés) es un trastorno inflamatorio sistémico de etiología desconocida que puede progresar a un curso crónico. La anemia de enfermedades crónicas puede ocurrir en pacientes con alteraciones inmunes agudas o crónicas, y se asocia con la producción de citoquinas proinflamatorias.

Palabras clave:

Enfermedad de Still del adulto

Refractaria

Golimumab

E-mail address: lorenabrance@gmail.com

<https://doi.org/10.1016/j.rcreu.2018.10.010>

0121-8123/© 2018 Published by Elsevier España, S.L.U. on behalf of Asociación Colombiana de Reumatología.

Caso clínico: Se presenta el caso de una mujer de 61 años con varios episodios de faringitis, fiebre aguda, lesiones en piel salmón-rosadas evanescentes, anemia normocítica normocrómica, leucocitosis, trombocitopenia, poliartritis, disfunción hepática, aumento de la velocidad de eritrosedimentación y proteína C-reactiva y niveles notablemente altos de ferritina. Se diagnostica como enfermedad de Still del adulto después de descartar enfermedades secundarias. A pesar de los 8 meses de tratamiento con altas dosis de corticosteroides y metotrexato, la paciente empeoró la evolución clínica, con sinovitis importante, deformidades articulares que condujeron a una peor calidad de vida requiriendo ayuda para las actividades de la vida diaria. Luego de recibir golimumab anti-TNF α (50 mg/mes), se observó una rápida respuesta a partir del tercer mes de tratamiento. **Conclusión:** Golimumab mejoró la anemia, los niveles séricos de proteína C-reactiva, la poliartritis y la calidad de vida en una AOSD refractaria.

© 2018 Publicado por Elsevier España, S.L.U. en nombre de Asociación Colombiana de Reumatología.

Introduction

Adult onset Still's disease (AOSD) is a systemic inflammatory disorder. The diagnosis needs clinical suspicion and the exclusion of infection, malignancy and systemic disease. The most widely validated criteria are Yamaguchi's criteria. The presence of two or more major criteria has 96.2% sensitivity and 92.1% specificity for AOSD.¹ The annual incidence of AOSD is nearly to 0.16–0.4/100.000 adults.^{2,3}

AOSD is generally a mild and self-limiting disease (34%), but it could progress to intermittent course (24%), to a chronic course with relapse (36%) and occasional life-threatening complications in one-third of patients.⁴ Refractory systemic flares of the disease may potentially cause life-threatening conditions, such as macrophage activation syndrome, hepatic failure, disseminated intravascular coagulation, pericarditis, pleuritis, peritonitis, amyloidosis.⁵ Anemia could be one of the manifestations in AOSD, which is classified as anemia of chronic disease and it may occur in patients with acute or chronic immune activation associated with the production of proinflammatory cytokines. Chronic inflammation can modify the erythropoiesis, probably mediated by proinflammatory cytokines such as interleukin-1 (IL-1), TNF α and interferon- γ .⁶ It was previously reported the use of biologic agents in refractory AOSD which contributes to improve the course of the disease.^{7–10}

Case report

A previously healthy 61-year-old female patient started with several pharyngitis episodes. The last one was accompanied with spiking fever once a day to 39–40°C, usually in the evening or night, with concomitant salmon-colored rash of the trunk and extremities and severe polyarthritis with impaired activities of daily living. At physical examination the patient had polyarthritis in carpometacarpal, proximal and distal interfalangeal joints, elbows, shoulders, hips, knees, ankles and metatarsophalangeal (Fig. 1 left). Hepatomegaly was also detected. Positive laboratory findings: white blood cell count 16.500 mm³ (neutrophil 85%), hemoglobin 8.7 g/dl, hematocrit 33.3%, platelet count 80000 mm³, aspartate aminotransferase

180 mU/ml (normal range: <37 mU/ml), alanine aminotransferase 250 mU/ml (normal range: <65 mU/ml) and ferritin levels of 40 000 ng/ml (normal range: 10–277 ng/ml). The serological findings were: CRP 60 mg/dl (normal range <5.0), ESR: 120 mm 1/hour, rheumatoid factor: negative. Antinuclear antibodies, antideoxyribonucleic acid antibodies, myeloperoxidase antineutrophil cytoplasmic antibodies, proteinase 3 antineutrophil cytoplasmic antibodies, anti-cyclic citrullinated peptide antibodies and extractable nuclear antigens were negative. Serum protein electrophoresis and complement factor 3 (C3), C4 and CH50 were in normal range. Other autoimmune, infectious and neoplastic diseases were excluded. Chest X-ray, electrocardiogram and echocardiogram were normal. Thorax, abdominal and pelvis computed tomography scan were negative for a primary disease. Joint radiographs showed juxta-articular osteopenia. Accordingly, the patient was diagnosed as AOSD.

Prednisone 50 mg/day improved significantly and rapidly the liver test functions, leucocytosis, thrombocytopenia and arthralgias. Steroid dose was reduced progressively to 20 mg/day but disease recurrence occurred. The recurrence was characterized by severe arthritis which needed higher doses of prednisone. The patient also need pain medications at high doses: diclofenac, indomethacin and ibuprofen were indicated when each one failed. Methotrexate was also initiated because the aggressive course of the disease and the high dose of steroid required. Despite treatment with methotrexate 25 mg/week and prednisone 30 mg/day an improvement was not observed. Persistent anemia, polyarthritis, and fever were observed. The patient could not walk and could not perform activities of daily living. Therefore golimumab 50 mg/monthly was indicated. After three month of golimumab treatment an improved in pain, synovitis (Fig. 1 right), anemia and daily activities was observed. The laboratory findings after eight month of golimumab treatment were: white blood cell count 6.000 mm³, hemoglobin 12.5 g/dl, hematocrit 40%, platelet count 245.000 mm³. The liver function tests, serum electrolytes and renal function were in normal range. ESR rate was 10 mm/1st hour and CRP was 6.2 mg/l. The hemoglobin and CRP changes over time are shown in Fig. 2. Joint radiographs performed at the follow-up evaluation had not joint destruction.



Fig. 1 – Left. Persistent synovitis in hands and knees in a patient with refractory adult onset Still's disease treated with prednisone and methotrexate. Right. Rapid responses after golimumab treatment.




Fig. 2 – Hemoglobin and serum C-reactive protein levels (CRP) changes over time in a patient with refractory adult onset Still's disease. Abbreviations: pred = prednisone; mtz = methotrexate.

Remission has been maintained for 36 months with prednisone 5 mg/day, methotrexate 15 mg/week and golimumab 50 mg/month and pain medication is not required. The patient can do activities of daily living, walk and also ride a bike.

Informed consent was obtained from the patient reported in this article.

Discussion

AOSD is a disease of young adults but can affect patients older than 60 years of age.¹¹ Pathogenesis of AOSD remains partially unknown but a major role has been recently attributed

to proinflammatory Th1 cytokines, including TNF- α , IL-1, IL-6 and IL-18.⁶

AOSD is generally a mild and self-limiting disease but it could progress to a chronic course in 36% of the cases. The elevated ESR and corticosteroids refractoriness were associated with poor prognosis.⁴

Kim et al.⁵ studied 54 Korean patients with AOSD. Forty two percent of these patients were resistant to corticosteroids while methotrexate was the most commonly used disease modifying anti-rheumatic drugs (50%). The corticosteroid requirements were lower in the methotrexate responsive patients. Disease refractory to conventional treatment has led to the use of biologic therapy including anti-TNF- α (etanercept, infliximab and adalimumab), anakinra, tocilizumab, abatacept and rituximab.⁶⁻⁹

This case report had all the Yamaguchi's criteria diagnostic; other immunologic, infectious and cancer were ruled out. Because of refractory and aggressive joint disease golimumab – a humanized monoclonal anti-TNF α – was indicated as other biological agents were previously reported.

Multiple clinical cases using etanercept have been reported which are summarized by Kiyonaga et al.¹² Among them there are three case series with 12, 10 and 4 patients.¹³⁻¹⁵ Infliximab was used as anti-TNF α in AOSD¹⁴⁻¹⁸ and also in aggressive cases with good response.^{19,20} The use of adalimumab in AOSD has been reported in two cases: one patient with favorable response²¹ and another patient without favorable response.²² No data were found about golimumab.

Besides anti-TNF- α agents, other immunosuppressive treatments were also reported. Anakinra also showed good response in case series of AOSD resistant to conventional

immunosuppressive treatment.²³⁻³⁰ A multicenter study of 41 patients showed that anakinra is associated with rapid and sustained clinical and laboratory improvement, even in non-responders to other biologic agents, but joint manifestations were more refractory than the systemic manifestations.³⁰

The efficacy of tocilizumab in patients with AOSD with inadequate response to corticosteroids and standard synthetic immunosuppressive drug or anti-TNF- α has been reported. Tocilizumab was associated with a rapid improvement in refractory AOSD but joint manifestations seem to be more refractory than systemic manifestations.^{31,15,32,33,34,35}

Limited data about abatacept and rituximab in refractory AOSD are available. A few patients have been reported. Abatacept was reported in one patient resistant to DMARDs³⁶ and in other one resistant to DMARDs, anti-IL-1 and anti-TNF- α therapies.³⁷ Rituximab has also shown efficacy in AOSD.^{38,39}

Due to severe joint involvement an anti-TNF agent was used. Among them golimumab was selected since it is administered subcutaneously monthly as the patient lived in a small village without possibility of intravenous administration. Also, the patient had severe anemia and golimumab had been shown to improve hemoglobin levels as described below. Anemia of chronic disease may occur in patients with acute or chronic immune activation and is associated with the production of proinflammatory cytokines.⁵ It has been reported that lower hemoglobin levels were associated with increased disease activity and anemia contributed independently to physical disability in patients with rheumatoid arthritis.^{40,41} The anemia improvement requires a treatment of the underlying inflammatory cause. Patients under golimumab treatment significantly improved hemoglobin levels. In patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis ($n = 2303$) treated with golimumab hemoglobin levels increase from baseline to week 14, 0.9 g/dl in anemic patients and 0.3 g/dl in control subjects. This increased was higher when anemia was due to inflammatory cause (1.4 g/dl).⁴²

In this case report, during the first three month of golimumab treatment the hemoglobin levels were in a plateau and after that an increase in an average of 0.86 g/dl/month was observed (5.2 g/dl in five months).

Conclusion

Golimumab treatment improved the course of the disease, polyarthritis and quality of live in a refractory AOSD.

Conflict of interest

María Lorena Brance declare that she has no conflict of interest.

REFERENCES

1. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still's disease. *J Rheumatol*. 1992;19:424-30.
2. Magadur-Joly G, Billaud E, Barrier JH, Pennec YL, Masson C, Renou P, et al. Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France. *Ann Rheum Dis*. 1995;54:587-90.
3. Evensen KJ, Nossent HC. Epidemiology and outcome of adult-onset Still's disease in Northern Norway. *Scand J Rheumatol*. 2006;35:48-51.
4. Pouchot J, Sampalis JS, Beaudet F, Carette S, Décary F, Salusinsky-Sternbach M, et al. Adult Still's disease: manifestations, disease course, and outcome in 62 patients. *Medicine (Baltimore)*. 1991;70:118-36.
5. Kim HA, Sung JM, Suh CH. Therapeutic responses and prognosis in adult-onset Still's disease. *Rheumatol Int*. 2012;32:1291-8.
6. Macdougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. *Nephrol Dial Transplant*. 2002;11:39-43.
7. Pouchot J, Arlet JB. Biological treatment in adult-onset Still's disease. *Best Pract Res Clin Rheumatol*. 2012;26:477-87.
8. Jamilloux Y, Gerfaud-Valentin M, Henry T, Sève P. Treatment of adult-onset Still's disease: a review. *Ther Clin Risk Manag*. 2014;11:33-43.
9. Al-Homood IA. Biologic treatments for adult-onset Still's disease. *Rheumatology (Oxford)*. 2014;53:32-8.
10. Cavalli G, Franchini S, Aiello P, Guglielmi B, Berti A, Campochiaro C, et al. Efficacy and safety of biological agents in adult-onset Still's disease. *Scand J Rheumatol*. 2015;6:1-6.
11. Wouters JM, van Rijswijk MH, van de Putte LB. Adult onset Still's disease in the elderly: a report of two cases. *J Rheumatol*. 1985;12:791-3.
12. Kiyonaga Y, Maeshima K, Imada C, Haranaka M, Ishii K, Shibata H. Steroid-sparing effects of etanercept in a patient with steroid-dependent adult-onset Still's disease. *Intern Med*. 2014;53:1209-13.
13. Husni ME, Maier AL, Mease PJ, Overman SS, Fraser P, Gravalles EM, et al. Etanercept in the treatment of adult patients with Still's disease. *Arthritis Rheum*. 2002;46:1171-6.
14. Fautrel B, Sibilia J, Mariette X, Combe B. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. *Ann Rheum Dis*. 2005;64:262-6.
15. Suematsu R, Ohta A, Matsuura E, Takahashi H, Fujii T, Horiuchi T, et al. Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan. *Mod Rheumatol*. 2012;22:712-9.
16. Cavagna L, Caporali R, Epis O, Bobbio-Pallavicini F, Montecucco C. Infliximab in the treatment of adult Still's disease refractory to conventional therapy. *Clin Exp Rheumatol*. 2001;19:329-32.
17. Kraetsch HG, Antoni C, Kalden JR, Manger B. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. *Ann Rheum Dis*. 2001;60, iii55-7.
18. Kokkinos A, Iliopoulos A, Greka P, Efthymiou A, Katsilambros N, Sfrikakis PP. Successful treatment of refractory adult-onset Still's disease with infliximab. A prospective, non-comparative series of four patients. *Clin Rheumatol*. 2004;23:45-9.
19. Babacan T, Onat AM, Pehlivan Y, Comez G, Karakök M. Successful treatment of refractory adult Still's disease and membranous glomerulonephritis with infliximab. *Clin Rheumatol*. 2010;29:423-6.
20. Fujii K, Rokutanda R, Osugi Y, Koyama Y, Ota T. Adult-onset Still's disease complicated by autoimmune hepatitis: successful treatment with infliximab. *Intern Med*. 2012;51:1125-8.
21. Benucci M, Li GF, Del Rosso A, Manfredi M. Adalimumab (anti-TNF-alpha) therapy to improve the clinical course of

- adult-onset Still's disease: the first case report. *Clin Exp Rheumatol*. 2005;23:733.
22. Dechant C, Schauenberg P, Antoni CE, Kraetsch HG, Kalden JR, Manger B. Longterm outcome of TNF blockade in adult-onset Still's disease. *Dtsch Med Wochenschr*. 2004;129:1308-12.
 23. Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. *Arthritis Rheum*. 2005;52:1794-803.
 24. Kalliolias GD, Georgiou PE, Antonopoulos IA, Andonopoulos AP, Liossis SN. Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. *Ann Rheum Dis*. 2007;66:842-3.
 25. Kötter I, Wacker A, Koch S, Henes J, Richter C, Engel A, et al. Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. *Semin Arthritis Rheum*. 2007;37:189-97.
 26. Lequerré T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. *Ann Rheum Dis*. 2008;67:302-8.
 27. Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study. *Arthritis Res Ther*. 2011;13:R91.
 28. Nordström D, Knight A, Luukkainen R, van Vollenhoven R, Rantalaiho V, Kajalainen A, et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study. *J Rheumatol*. 2012;39:2008-11.
 29. Giampietro C, Ridene M, Lequerre T, Costedoat Chalumeau N, Amoura Z, Sellam J, et al. Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy. *Arthritis Care Res (Hoboken)*. 2013;65:822-6.
 30. Ortiz-Sanjuán F, Blanco R, Riancho-Zarrabeitia L, Castañeda S, Olivé A, Riveros A, et al. Efficacy of anakinra in refractory adult-onset Still's disease: multicenter study of 41 patients and literature review. *Medicine (Baltimore)*. 2015;94:e1554.
 31. Puéchal X, DeBandt M, Berthelot JM, Breban M, Dubost JJ, Fain O, et al. Tocilizumab in refractory adult Still's disease. *Arthritis Care Res (Hoboken)*. 2011;63:155-9.
 32. Ortiz-Sanjuán F, Blanco R, Calvo-Rio V, Narvaez J, Rubio Romero E, Olivé A, et al. Efficacy of tocilizumab in refractory adult-onset still's disease: multicenter retrospective open-label study of 34 patients. *Arthritis Rheumatol*. 2014;66:1659-65.
 33. Bannai E, Yamashita H, Kaneko S, Ueda Y, Ozaki T, Tsuchiya H, et al. Successful tocilizumab therapy in seven patients with refractory adult-onset Still's disease. *Mod Rheumatol*. 2016;26:297-301.
 34. Cipriani P, Ruscitti P, Carubbi F, Pantano I, Liakouli V, Berardicurti O, et al. Tocilizumab for the treatment of adult-onset Still's disease: results from a case series. *Clin Rheumatol*. 2014;33:49-55.
 35. Elkayam O, Jiries N, Dranitzki Z, Kivity S, Lidar M, Levy O, et al. Tocilizumab in adult-onset Still's disease: the Israeli experience. *J Rheumatol*. 2014;41:244-7.
 36. Ostrowski RA, Tehrani R, Kadanoff R. Refractory adult-onset still disease successfully treated with abatacept. *J Clin Rheumatol*. 2011;17:315-7.
 37. Quartuccio L, Maset M, De Vita S. Efficacy of abatacept in a refractory case of adult-onset Still's disease. *Clin Exp Rheumatol*. 2010;28:265-7.
 38. Lee WS, Yoo WH. (2014) Rituximab for refractory adult-onset Still's disease with thrombotic microangiopathy. *Rheumatology (Oxford)*. 2010;53: 1717-8.
 39. Bartoloni E, Alunno A, Luccioli F, Santoboni G, Gerli R. Successful treatment of refractory adult-onset Still's disease with anti-CD20 monoclonal antibody. *Clin Exp Rheumatol*. 2009;27:888-9.
 40. Wolfe F, Michaud K. Anemia and renal function in patients with rheumatoid arthritis. *J Rheumatol*. 2006;33: 1516-22.
 41. Han C, Rahman MU, Doyle MK, Bathon JM, Smolen J, Kavanaugh A, et al. Association of anemia and physical disability among patients with rheumatoid arthritis. *J Rheumatol*. 2007;34:2177-82.
 42. Furst DE, Kay J, Wasko MC, Keystone E, Kavanaugh A, Deodhar A, et al. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. *Rheumatology (Oxford)*. 2013;52:1845-55.